{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:38:48Z","timestamp":1792647528111,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100003359","name":"Scoliosis Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.178113","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T06:55:35Z","timestamp":1756450535000},"page":"178113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Multifaceted safety concerns of glibenclamide in managing type 2 diabetes: Evidence from real-world adverse event analysis"],"prefix":"10.1016","volume":"1005","author":[{"given":"Mengyuan","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mixue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huqiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejphar.2025.178113_bib1","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2337\/dci23-0017","article-title":"Diabetes medication changes in older adults with type 2 diabetes: insights into physician factors and questions ahead","volume":"46","author":"Alexopoulos","year":"2023","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2025.178113_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13300-020-00811-3","article-title":"The place of sulfonylureas in guidelines: why are there differences?","volume":"11","author":"Amod","year":"2020","journal-title":"Diabetes Ther."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178113_bib3","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/bcp.13059","article-title":"Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta\u2010analysis","volume":"82","author":"Andersen","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.ejphar.2025.178113_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106072","article-title":"Selection of essential medicines for diabetes in low and middle income countries: a survey of 32 national essential medicines lists","volume":"9","author":"Bazargani","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178113_bib5","article-title":"Cost-effectiveness of saxagliptin compared with glibenclamide as a second-line therapy added to metformin for type 2 diabetes mellitus in Ethiopia","volume":"6","author":"Bekele","year":"2021","journal-title":"MDM Policy Pract."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178113_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178113_bib7","first-page":"19","volume":"66","author":"Caballero-Corchuelo","year":"2019","journal-title":"Endocrinol. Diabetes Nutr. (Engl Ed)"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178113_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.diabres.2015.07.002","article-title":"Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents","volume":"110","author":"Chan","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178113_bib9","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jhep.2005.02.011","article-title":"Cholestatic liver injury after glimepiride therapy","volume":"42","author":"Chounta","year":"2005","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.ejphar.2025.178113_bib10","doi-asserted-by":"crossref","first-page":"9357","DOI":"10.3390\/ijms24119357","article-title":"Effects of hypoglycemia on cardiovascular function in patients with diabetes","volume":"24","author":"Christou","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178113_bib11","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/cpt.2975","article-title":"Pharmacologic heterogeneity and risk of severe hypoglycemia with concomitant use of sulfonylureas and DPP-4 inhibitors: population-based cohort study","volume":"114","author":"Dimakos","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178113_bib12","article-title":"Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study","volume":"362","author":"Douros","year":"2018","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ejphar.2025.178113_bib13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ejphar.2025.178113_bib14","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/0168-8227(91)90010-B","article-title":"Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM","volume":"14","author":"Harrower","year":"1991","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2025.178113_bib15","article-title":"Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis","volume":"16","author":"He","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178113_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/2042018816632440","article-title":"Glibenclamide-induced profound hypoglycaemic crisis: a case report","volume":"7","author":"Hussain","year":"2016","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2025.178113_bib17","doi-asserted-by":"crossref","DOI":"10.24966\/DMD-201X\/100028","article-title":"Glipizide induced hepatotoxicity: a case report and review of literature","author":"Kamal","year":"2019","journal-title":"Diab. Metab. Disord"},{"issue":"18","key":"10.1016\/j.ejphar.2025.178113_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026289","article-title":"Sulfonylurea is associated with higher risks of ventricular arrhythmia or sudden cardiac death compared with metformin: a population\u2010based cohort study","volume":"11","author":"Lee","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178113_bib20","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1038\/s41598-023-33542-z","article-title":"Hypoglycemia risk with inappropriate dosing of glucose-lowering drugs in patients with chronic kidney disease: a retrospective cohort study","volume":"13","author":"Li","year":"2023","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178113_bib21","doi-asserted-by":"crossref","DOI":"10.1530\/EC-24-0404","article-title":"Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system","volume":"13","author":"Liang","year":"2024","journal-title":"Endocr Connect"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178113_bib22","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2337\/dc20-0876","article-title":"Glucose control, sulfonylureas, and insulin treatment in elderly people with type 2 diabetes and risk of severe hypoglycemia and death: an observational study","volume":"44","author":"Ling","year":"2021","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178113_bib23","article-title":"A real-world pharmacovigilance study of certolizumab pegol based on FAERS database","volume":"15","author":"Liu","year":"2025","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.ejphar.2025.178113_bib24","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1111\/dom.15917","article-title":"Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: a cohort study","volume":"26","author":"Long","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.178113_bib25","first-page":"46","article-title":"Severe hypoglycemia in patients with known diabetes requiring emergency department care: a report from an Italian multicenter study","volume":"5","author":"Mantovani","year":"2016","journal-title":"J. Clin. Transl. Endocrinol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178113_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41392-025-02157-3","article-title":"Glibenclamide targets MDH2 to relieve aging phenotypes through metabolism-regulated epigenetic modification","volume":"10","author":"Mao","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.178113_bib27","article-title":"Sulfonylureas as second line treatment for type 2 diabetes","volume":"362","author":"McGowan","year":"2018","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.ejphar.2025.178113_bib28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/dom.12287","article-title":"A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes. Metabol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178113_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American diabetes association and the European association for the study of diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1016\/j.ejphar.2025.178113_bib30","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.3390\/diagnostics14242829","article-title":"Gastrointestinal safety assessment of GLP-1 receptor agonists in the US: a real-world adverse events analysis from the FAERS database","volume":"14","author":"Osei","year":"2024","journal-title":"Diagnostics"},{"issue":"8","key":"10.1016\/j.ejphar.2025.178113_bib31","first-page":"138","article-title":"Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance","volume":"10","author":"Park","year":"2020","journal-title":"Life Basel Switz"},{"issue":"7","key":"10.1016\/j.ejphar.2025.178113_bib32","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2337\/diacare.20.7.1215b","article-title":"Glibenclamide and liver disease","volume":"20","author":"Petrogiannopoulos","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2025.178113_bib33","first-page":"83","article-title":"Population pharmacokinetic modeling of glibenclamide in poorly controlled South African type 2 diabetic subjects","volume":"8","author":"Rambiritch","year":"2016","journal-title":"Clin. Pharmacol. Adv. Appl."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178113_bib34","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.2337\/db13-0216","article-title":"Severe hypoglycemia\u2013induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation","volume":"62","author":"Reno","year":"2013","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.ejphar.2025.178113_bib35","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2337\/dc22-0772","article-title":"Cardiovascular and renal benefits of novel diabetes drugs by baseline cardiovascular risk: a systematic review, meta-analysis, and meta-regression","volume":"46","author":"Rodriguez-Valadez","year":"2023","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ejphar.2025.178113_bib36","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2337\/dc20-3045","article-title":"American diabetes association framework for glycemic control in older adults: implications for risk of hospitalization and mortality","volume":"44","author":"Rooney","year":"2021","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ejphar.2025.178113_bib37","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s13300-024-01612-8","article-title":"Current position of gliclazide and sulfonylureas in the contemporary treatment paradigm for type 2 diabetes: a scoping review","volume":"15","author":"Sahin","year":"2024","journal-title":"Diabetes Ther."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178113_bib38","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"issue":"7","key":"10.1016\/j.ejphar.2025.178113_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.23067","article-title":"Cardiovascular events in individuals treated with sulfonylureas or dipeptidyl peptidase 4 inhibitors","volume":"8","author":"Turchin","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178113_bib40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12902-022-01158-5","article-title":"Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs","volume":"22","author":"Volke","year":"2022","journal-title":"BMC Endocr. Disord."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178113_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.45854","article-title":"Comparison of mitochondrial adenosine triphosphate\u2013sensitive potassium channel High- vs low-affinity sulfonylureas and cardiovascular outcomes in patients with type 2 diabetes treated with metformin","volume":"5","author":"Wang","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178113_bib42","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Wang","year":"2024","journal-title":"Andrology"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178113_bib43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA adverse event reporting system (FAERS) database","volume":"19","author":"Yang","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejphar.2025.178113_bib44","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2024.2343015","article-title":"Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms","author":"Yoosuf","year":"2024","journal-title":"Expet Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178113_bib45","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/dom.14666","article-title":"Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: a meta-analysis and meta-regression analysis","volume":"24","author":"Yoshiji","year":"2022","journal-title":"Diabetes Obes. Metabol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178113_bib46","doi-asserted-by":"crossref","first-page":"317.e11","DOI":"10.1016\/j.amjmed.2017.09.044","article-title":"Sulfonylureas as initial treatment for type 2 diabetes and the risk of severe hypoglycemia","volume":"131","author":"Yu","year":"2018","journal-title":"Am. J. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178113_bib48","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA adverse event reporting system (FAERS) database","volume":"19","author":"Zhao","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejphar.2025.178113_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2025.2520422","article-title":"Comprehensive post-marketing safety analysis of tildrakizumab: insights from the FDA adverse event reporting system","author":"Zhao","year":"2025","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejphar.2025.178113_bib50","doi-asserted-by":"crossref","DOI":"10.1007\/s11096-025-01896-1","article-title":"Real-world safety of deucravacitinib: insights from the food and drug administration adverse event reporting system","author":"Zhao","year":"2025","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.ejphar.2025.178113_bib47","doi-asserted-by":"crossref","first-page":"1458438","DOI":"10.3389\/fphar.2024.1458438","article-title":"Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178113_bib51","doi-asserted-by":"crossref","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","article-title":"A real-world disproportionality analysis of everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.ejphar.2025.178113_bib52","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/14740338.2024.2410436","article-title":"A real-world pharmacovigilance study using disproportionality analysis of United States food and drug administration adverse event reporting system events for vinca alkaloids: comparing vinorelbine and vincristine","volume":"23","author":"Zhong","year":"2024","journal-title":"Expet Opin. Drug Saf."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:52:56Z","timestamp":1758055976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925008672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":51,"alternative-id":["S0014299925008672"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178113","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multifaceted safety concerns of glibenclamide in managing type 2 diabetes: Evidence from real-world adverse event analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178113"}}